Hookipa Pharma Inc. shares rise 3.30% intraday after Gilead Sciences receives positive CHMP opinions for lenacapavir.

Hookipa Pharma Inc. rose 3.30% in intraday trading, with the company's stock price movement aligning with positive news from Gilead Sciences, Inc. Gilead Sciences received backing from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its twice-yearly lenacapavir injection for HIV prevention. This recommendation, if approved by the European Commission, could make lenacapavir the EU's first twice-yearly HIV prevention option, offering a long-acting alternative to daily oral pills and other shorter-acting options.